These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 14534297)

  • 21. Stabilising the DNA-binding domain of p53 by rational design of its hydrophobic core.
    Khoo KH; Joerger AC; Freund SM; Fersht AR
    Protein Eng Des Sel; 2009 Jul; 22(7):421-30. PubMed ID: 19515728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms.
    Jeffrey PD; Gorina S; Pavletich NP
    Science; 1995 Mar; 267(5203):1498-502. PubMed ID: 7878469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.
    Bullock AN; Henckel J; Fersht AR
    Oncogene; 2000 Mar; 19(10):1245-56. PubMed ID: 10713666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutational analysis of the p53 core domain L1 loop.
    Zupnick A; Prives C
    J Biol Chem; 2006 Jul; 281(29):20464-73. PubMed ID: 16687402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [P53 at the atomic scale: the multiple faces of a crystal].
    Hainaut P
    Bull Cancer; 1997 Jul; 84(7):747-51. PubMed ID: 9339202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for "mutant conformation".
    Friedler A; DeDecker BS; Freund SM; Blair C; Rüdiger S; Fersht AR
    J Mol Biol; 2004 Feb; 336(1):187-96. PubMed ID: 14741214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
    Sigal A; Rotter V
    Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.
    Kamada R; Nomura T; Anderson CW; Sakaguchi K
    J Biol Chem; 2011 Jan; 286(1):252-8. PubMed ID: 20978130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein.
    Martin AC; Facchiano AM; Cuff AL; Hernandez-Boussard T; Olivier M; Hainaut P; Thornton JM
    Hum Mutat; 2002 Feb; 19(2):149-64. PubMed ID: 11793474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stability of the core domain of p53: insights from computer simulations.
    Madhumalar A; Smith DJ; Verma C
    BMC Bioinformatics; 2008; 9 Suppl 1(Suppl 1):S17. PubMed ID: 18315848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure and Function of p53-DNA Complexes with Inactivation and Rescue Mutations: A Molecular Dynamics Simulation Study.
    Kamaraj B; Bogaerts A
    PLoS One; 2015; 10(8):e0134638. PubMed ID: 26244575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-function-rescue: the diverse nature of common p53 cancer mutants.
    Joerger AC; Fersht AR
    Oncogene; 2007 Apr; 26(15):2226-42. PubMed ID: 17401432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solvent-exposed residues located in the beta-sheet modulate the stability of the tetramerization domain of p53--a structural and combinatorial approach.
    Mora P; Carbajo RJ; Pineda-Lucena A; Sánchez del Pino MM; Pérez-Payá E
    Proteins; 2008 Jun; 71(4):1670-85. PubMed ID: 18076077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recognition of DNA by p53 core domain and location of intermolecular contacts of cooperative binding.
    Rippin TM; Freund SM; Veprintsev DB; Fersht AR
    J Mol Biol; 2002 May; 319(2):351-8. PubMed ID: 12051912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs.
    Joerger AC; Ang HC; Fersht AR
    Proc Natl Acad Sci U S A; 2006 Oct; 103(41):15056-61. PubMed ID: 17015838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamic perspectives into the mechanisms of mutation-induced p53-DNA binding loss and inactivation using active perturbation theory: Structural and molecular insights toward the design of potent reactivators in cancer therapy.
    Olotu FA; Soliman MES
    J Cell Biochem; 2019 Jan; 120(1):951-966. PubMed ID: 30160791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains.
    Ang HC; Joerger AC; Mayer S; Fersht AR
    J Biol Chem; 2006 Aug; 281(31):21934-21941. PubMed ID: 16754663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conformational effects of selected cancer-related amino acid substitutions in the p53 protein.
    Brandt-Rauf PW; De Vivo I; Dykes DC; Pincus MR
    J Biomol Struct Dyn; 1992 Oct; 10(2):253-64. PubMed ID: 1466808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural studies of p53 inactivation by DNA-contact mutations and its rescue by suppressor mutations via alternative protein-DNA interactions.
    Eldar A; Rozenberg H; Diskin-Posner Y; Rohs R; Shakked Z
    Nucleic Acids Res; 2013 Oct; 41(18):8748-59. PubMed ID: 23863845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants.
    Friedler A; Hansson LO; Veprintsev DB; Freund SM; Rippin TM; Nikolova PV; Proctor MR; Rüdiger S; Fersht AR
    Proc Natl Acad Sci U S A; 2002 Jan; 99(2):937-42. PubMed ID: 11782540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.